MDAI Spectral AI, Inc.

BULLISH Impact: 8/10 PRESS-RELEASE
Horizon months Filed Mar 18, 2026 Processed 2mo ago Wire GlobeNewswire
Press release: contract
Latest settled — T+20d
MDAI ▲ +33.10% at T+20d
LONG call ✓ call won +33.10% · α vs SPY +25.48% · entry $1.42 → $1.89
Next anchor: T+60d due 24h ago
Currently $1.82 · +28.17% from $1.42 entry
Entry anchored
Mar 18, 03:59 PM ET
via Databento tick
T+1d
+8.45%
call +8.45% · α +10.19%
$1.54
settled 3mo ago
T+5d
+7.04%
call +7.04% · α +9.25%
$1.52
settled 3mo ago
T+20d
+33.10%
call +33.10% · α +25.48%
$1.89
settled 8w ago
T+60d
call — · α —
due 24h ago

Price Chart

Loading chart...

Executive Summary

Spectral AI (MDAI) announced $31.7 million in additional non-dilutive funding from BARDA to advance development of its DeepView® System, an AI-powered burn wound imaging technology. The funding accelerates Phase II development, including total body surface area mapping, and supports FDA clearance efforts. The company is also contributing $9.7 million to the project, which is part of a larger contract valued up to $150 million.

Key Financial Metrics

Deal Value
$31.7M

Actionable Insight

This funding de-risks the path to FDA authorization and commercialization of the DeepView System. Traders should monitor for upcoming FDA decision timelines and potential near-term catalysts. The non-dilutive nature of the funding is a positive signal for shareholders, avoiding near-term equity dilution.

Key Facts

  • Spectral AI received $31.7 million in new non-dilutive funding from BARDA.
  • Company committed to contribute an additional $9.7 million to development costs.
  • Total BARDA contract value remains up to $150 million, with $54.9 million previously committed and now $31.7 million newly advanced.
  • Funding supports FDA clearance and development of DeepView System, including total body surface area mapping.
  • DeepView System targets use in emergency departments, trauma centers, and as a medical countermeasure for mass burn incidents.

Financial Impact

$31.7 million in non-dilutive capital received, reducing near-term financing risk; $9.7 million in additional company investment

cashR&D spenddilution

Risk Factors

  • FDA clearance is not guaranteed and remains a key regulatory hurdle.
  • Commercial adoption may be slow despite government support.
  • Company must still contribute $9.7 million, which could pressure cash reserves if not offset by future funding.

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258593
3 reports for MDAI
Performance horizon
Filters
Rows
Reports for MDAI — sortable, filterable
Type Now
Mar 24, 2026
11w ago
Press Release
MIXED ★ 6/10
$1.54 $1.80▲ +16.88%▲ +9.02%$1.82 (+18.18%)
Mar 18, 2026
12w ago
Press Release
BULLISH ★ 8/10
$1.42 $1.89▲ +33.10%▲ +25.48%$1.82 (+28.17%)
Mar 10, 2026
13w ago
Press Release
NEUTRAL ★ 3/10
$1.40 $1.68▲ +20.00%▲ +20.16%$1.82 (+30.00%)
Showing 3 of 3

US Market Status

Market Closed — Opens Mon (49h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access